Department of Environmental Biochemistry, ICMR- National Institute for Research in Environmental Health, Bhopal, India.
School of Biosciences, Apeejay Stya University, Gurgaon, India.
Expert Rev Mol Diagn. 2021 Jul;21(7):703-721. doi: 10.1080/14737159.2021.1920397. Epub 2021 Jul 2.
Accurate determination of the aberrantly expressed biomarkers such as human epidermal growth factor receptor 2 (HER2), carcinoembryonic antigen (CEA), platelet-derived growth factor (PDGF), mucin 1 (MUC1), and vascular endothelial growth factor VEGF have played an essential role in the clinical management of the breast cancer. Assessment of these cancer-specific biomarkers has conventionally relied on time-taking methods like the enzyme-linked immunosorbent assay and immunohistochemistry. However, recent development in the aptamer-based diagnostics has allowed developing tools that may substitute the conventional means of biomarker assessment in breast cancer. Adopting the aptamer-based diagnostic tools (aptasensors) to clinical practices will depend on their analytical performance on clinical samples.
In this review, we provide an overview of the analytical merits of HER2, CEA, PDGF, MUC1, and VEGF aptasensors. Scopus and Pubmed databases were searched for studies reporting aptasensor development for the listed breast cancer biomarkers in the past one decade. Linearity, detection limit, and response time are emphasized.
In our opinion, aptasensors have proven to be on a par with the antibody-based methods for detection of various breast cancer biomarkers. Though robust validation of the aptasensors on significant sample size is required, their ability to detect pathophysiological range of biomarkers suggest the possibility of future clinical adoption.
准确测定异常表达的生物标志物，如人表皮生长因子受体 2（HER2）、癌胚抗原（CEA）、血小板衍生生长因子（PDGF）、黏蛋白 1（MUC1）和血管内皮生长因子 VEGF，在乳腺癌的临床管理中发挥了重要作用。这些癌症特异性生物标志物的评估传统上依赖于耗时的方法，如酶联免疫吸附测定和免疫组织化学。然而，基于适配体的诊断方法的最新发展允许开发可能替代乳腺癌中生物标志物评估常规方法的工具。采用基于适配体的诊断工具（适配体传感器）进行临床实践将取决于它们在临床样本上的分析性能。
在这篇综述中，我们概述了 HER2、CEA、PDGF、MUC1 和 VEGF 适配体传感器的分析优点。在过去十年中，我们在 Scopus 和 Pubmed 数据库中搜索了关于用于列出的乳腺癌生物标志物的适配体传感器开发的研究报告。强调了线性度、检测限和响应时间。
在我们看来，适配体传感器在检测各种乳腺癌生物标志物方面已被证明可与抗体方法相媲美。尽管需要对适配体传感器进行大量样本的稳健验证，但它们在检测病理生理范围内生物标志物的能力表明了未来临床采用的可能性。
